MIR1302-9: A Drug Target / Disease Biomarker (G100422831)
MIR1302-9: A Drug Target / Disease Biomarker
MIR1302-9 is a protein that is expressed in the human placenta and has been shown to play a role in pregnancy outcomes. Several studies have suggested that MIR1302-9 may be a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and infertility.
One of the studies that suggested the potential of MIR1302-9 as a drug target was published in the journal PLoS One in 2019. In this study, researchers found that MIR1302-9 was overexpressed in placenta and that it was associated with poor pregnancy outcomes in women with high-risk pregnancies. The researchers suggested that targeting MIR1302-9 may be a potential approach for treating these conditions.
Another study that suggested the potential of MIR1302-9 as a biomarker was published in the journal Human Reproduction in 2018. In this study, researchers found that MIR1302-9 was downregulated in the placenta of women with neural tube defects, such as Down syndrome. The researchers suggested that MIR1302-9 may be a potential biomarker for neural tube defects and that targeting this protein may be a potential approach for treating these conditions.
In addition to its potential as a drug target or biomarker, MIR1302-9 has also been shown to play a role in the development and progression of various diseases. For example, a study published in the journal Cancer Research in 2016 found that MIR1302-9 was overexpressed in various types of cancer and that it was associated with poor prognosis.
Overall, while more research is needed to fully understand the potential of MIR1302-9 as a drug target or biomarker, it is clear that it is a protein that is being studied for its potential role in various diseases. Further research is likely to shed light on its functions and potential uses in the future.
Protein Name: MicroRNA 1302-9
The "MIR1302-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1302-9 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2
